For a patient with previously relapsed TTP but in clinical remission, what is the role of rituximab in treating asymptomatic ADAMTS13 deficiency to prevent relapse?

Topics: Medical Oncology • Hematology • Benign Hematology

Rituximab has entered the treatment algorithm in the first-line setting for the initial treatment of TTP. However, in remission, the role of adjuvant rituximab or preemptive rituximab in response to declining ADAMTS13 levels is more nuanced.

Should an asymptomatic patient, already treated with a 4-week course of rituximab, be retreated for a second occurrence of reduced ADATMS13 activity < 10%?

When do you consider maintenance rituximab?

Answer from: at Community Practice

A very good and interesting question. In remission, there is no question that severely deficient ADAMTS13 activity (<10%) is a strong risk factor for relapse. In patients with a chronic relapsing TTP history (at least 2 episodes), the approach most commonly has been to treat them preemptively wit...

Comments

at The Cleveland Clinic
I agree with Dr. @Spero Cataland's response. My bi...

Related Questions